Takeda Pharmaceutical Company Ltd

Cosmo Pharmaceuticals N.V. and Takeda have renewed their multi-year manufacturing and supply agreement for Mesalazine MMX 1200 mg, an oral once-daily treatment for ulcerative colitis.

AC Immune's ACI-7104.056 anti-alpha-synuclein active immunotherapy demonstrated a 20-fold increase in anti-alpha-synuclein antibodies after four immunizations in the Phase 2 VacSYn trial for early Parkinson's disease.

Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for PB016, a proposed biosimilar to Entyvio (vedolizumab) targeting moderate-to-severe ulcerative colitis and Crohn's disease.

The osteosarcoma market in the 7MM is expected to grow significantly by 2034, driven by extensive R&D activities and the entry of novel therapies including OST-HER2, Naxitamab 15-096, and HALMB-0168.

The FDA has granted 510(k) clearance to Takeda's HyHub and HyHub Duo devices, which enable needle-free transfer of HYQVIA's dual-vial components for patients aged 17 and older.

Keros Therapeutics has dosed the first patient in the Phase 3 RENEW clinical trial evaluating elritercept for transfusion-dependent anemia in myelodysplastic syndromes.

The FDA has identified significant ocular toxicity concerns with GSK's Blenrep (belantamab mafodotin) ahead of a July 17 advisory committee meeting to review the drug's reintroduction to the U.S. market.

Ascentage Pharma completed a $192.3 million share placement that was oversubscribed by eight times, demonstrating strong investor confidence in the company's cancer-focused pipeline.

Hansa Biopharma has appointed Dr. Richard Philipson as Chief Medical Officer effective July 14, bringing over 25 years of industry experience to the commercial-stage biopharmaceutical company.

Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.